Although the median overall survival (OS) of MCL patients is 5–7 years [11], major advances in the treatment have been achieved in the last few years with the advent of novel targeted agents such as BTK inhibitors (BTKi). This evidence concerns the gene BTK and mantle cell lymphoma.